Research involving long-term survivors of childhood and adolescent cancer: Issues impacting design and conduct of clinical trials

Current Problems in Cancer

Volumn 27, Issue 4, 2003, Pages 225-235

  Murphy, Sharon B ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; RAZOXANE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; COMPETENCE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYTOTOXICITY; FINANCIAL MANAGEMENT; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEARING IMPAIRMENT; HEART CONTRACTION; HEART LEFT VENTRICLE FAILURE; HORMONAL THERAPY; HUMAN; INFERTILITY; INFORMATION PROCESSING; LUNG DISEASE; LYMPHOMA; META ANALYSIS; METHODOLOGY; OSTEOSARCOMA; OUTCOMES RESEARCH; PATIENT SELECTION; PRIVACY; PROSTATE CANCER; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SURVIVAL TIME; TRAINING; TREATMENT INDICATION; UNITED STATES; VALIDATION PROCESS;

EID: 0038712919     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0147-0272(03)00030-8     Document Type: Article

References (11)

1. Hewitt M, Simone J. Ensuring quality cancer care. Washington, DC: National Cancer Policy Board, Institute of Medicine, National Academy Press, 1999.
2. Testa MA, Simonson DC. Assessment of quality of life outcomes. N Engl J Med 1996;334:835-40.
3. Ellis PM. Attitudes toward and participation in randomized clinical trials in oncology: a review of the literature. Ann Oncol 2000;11:939-45.
4. Cech TR, Egan LW, Doyle C, et al. The biomedical research bottleneck. Science 2001;293:573.
5. Campbell EG, Weissman JS, Moy E, Blumenthal D. 2001. Status of clinical research in academic health centers: views from the research leadership. JAMA 2001;286:800-6.
6. Shalala D. Protecting research subjects - what must be done. N Engl J Med 2000;343:808-10.
7. Lipschultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43.
8. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
9. Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001;23:215-20.
10. Castleberry R. Biology and treatment of neuroblastoma. Pediatr Clin North Am 1997;44:919-37.
11. Link M, Shuster J, Donaldson S, et al. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med 1997;337:1259-66.